Abstract
The frequency of Ebola virus outbreaks has been increasing since 2017, resulting in an increase in the number of known survivors treated with specific molecules and others not identified by response teams in an emergency setting of new viruses such as SARS-CoV-2.We have shown that people discharged after two RT-PCR tests could be Ebola patients who presented with a pauci-symptomatic form and who presented after the viraemic phase. We have also shown that the production of anti-Ebola antibodies in people treated with anti-Ebola molecules appears to be delayed and that antibody levels drop very rapidly over time. Contrary to official reports on the number of confirmed COVID-19 cases in the Democratic Republic of the Congo, we have reported a very wide spread of SARS-CoV-2 in Kinshasa following the first wave of the pandemic.This work, conducted in the context of emerging disease studies, demonstrates on the one hand the importance of serology for understanding the evolution of newly identified or previously known emerging diseases and, on the other, the importance to contibue with studies in survivors of Ebola virus disease to prevent relapse, which could be possible factors for disease emergence